

Carlos Camps

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2705277/publications.pdf>

Version: 2024-02-01

169
papers

11,861
citations

66250

44
h-index

31191

106
g-index

185
all docs

185
docs citations

185
times ranked

13357
citing authors

#	ARTICLE	IF	CITATIONS
1	Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer. <i>Cancers</i> , 2022, 14, 307.	1.7	20
2	Analysis of Exosomal Cargo Provides Accurate Clinical, Histologic and Mutational Information in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 3216.	1.7	4
3	dPCR application in liquid biopsies: divide and conquer. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 3-15.	1.5	15
4	Update on systemic treatment in early triple negative breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098674.	1.4	19
5	3D printing novel in vitro cancer cell culture model systems for lung cancer stem cell study. <i>Materials Science and Engineering C</i> , 2021, 122, 111914.	3.8	32
6	Characterization of Circulating T Cell Receptor Repertoire Provides Information about Clinical Outcome after PD-1 Blockade in Advanced Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2021, 13, 2950.	1.7	12
7	Hipopigmentaci3n capilar y cut3nea secundaria a pazopanib. <i>Medicina Cl3nica</i> , 2021, 158, 246-246.	0.3	1
8	Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study. <i>Frontiers in Oncology</i> , 2021, 11, 695038.	1.3	3
9	Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data. <i>BMC Cancer</i> , 2021, 21, 977.	1.1	5
10	Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications. <i>JCO Oncology Practice</i> , 2021, 17, e1162-e1169.	1.4	0
11	Exosomal microRNAs in non-small cell lung cancer. <i>Translational Cancer Research</i> , 2021, 10, 0-0.	0.4	13
12	CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1074-1083.	1.3	14
13	Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q. <i>Journal of Thoracic Disease</i> , 2020, 12, 2771-2780.	0.6	13
14	A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 575-582.	1.5	21
15	Breakthrough cancer pain: review and calls to action to improve its management. <i>Clinical and Translational Oncology</i> , 2020, 22, 1216-1226.	1.2	17
16	Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro. <i>PLoS ONE</i> , 2020, 15, e0228909.	1.1	66
17	Patient Perspective on the Management of Cancer Pain in Spain. <i>Journal of Patient Experience</i> , 2020, 7, 1417-1424.	0.4	4
18	ECO Experts™ consensus on establishing renal cancer healthcare quality measures in Spain.. <i>Journal of Clinical Oncology</i> , 2020, 38, 220-220.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Evaluation of Spanish hospitals participating in the Quality Oncology Practice Initiative program.. Journal of Clinical Oncology, 2020, 38, 222-222.	0.8	0
20	Active study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP). Clinical and Translational Oncology, 2019, 21, 380-390.	1.2	10
21	How sustainable are new treatment strategies for NSCLC?. Lancet Respiratory Medicine, the, 2019, 7, 733-735.	5.2	5
22	Delphi Consensus on the Follow-up of Cancer Patients with Breakthrough Pain Under Opioid Treatment. SN Comprehensive Clinical Medicine, 2019, 1, 891-899.	0.3	0
23	<p>Working towards a consensus on the oncological approach of breakthrough pain: a Delphi survey of Spanish experts</p>. Journal of Pain Research, 2019, Volume 12, 2349-2358.	0.8	8
24	Lung tumorspheres reveal cancer stem cell-like properties and a score with prognostic impact in resected non-small-cell lung cancer. Cell Death and Disease, 2019, 10, 660.	2.7	68
25	Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study). Translational Lung Cancer Research, 2019, 8, 461-475.	1.3	38
26	Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. Lung Cancer, 2019, 134, 72-78.	0.9	24
27	Mujer de 68 años con síndrome de ojos bailarines. Medicina Clínica, 2019, 153, 475.	0.3	2
28	Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study). Lung Cancer, 2019, 135, 161-168.	0.9	10
29	Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2. Cancer Treatment and Research Communications, 2018, 15, 21-31.	0.7	9
30	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. Journal of Thoracic Oncology, 2018, 13, 413-425.	0.5	66
31	Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-mediated Effects. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1164-1176.	2.5	77
32	EpCAM duality becomes this molecule in a new Dr. Jekyll and Mr. Hyde tale. Critical Reviews in Oncology/Hematology, 2018, 126, 52-63.	2.0	26
33	Oncologists' knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study. Clinical and Translational Oncology, 2018, 20, 613-618.	1.2	13
34	Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients. Oncotarget, 2018, 9, 488-494.	0.8	30
35	Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. British Journal of Cancer, 2018, 119, 1464-1470.	2.9	62
36	Impact of DLK1-DIO3 imprinted cluster hypomethylation in smoker patients with lung cancer. Oncotarget, 2018, 9, 4395-4410.	0.8	37

#	ARTICLE	IF	CITATIONS
37	The clinical impact of using complex molecular profiling strategies in routine oncology practice. <i>Oncotarget</i> , 2018, 9, 20282-20293.	0.8	15
38	Exosomal microRNAs in liquid biopsies: future biomarkers for prostate cancer. <i>Clinical and Translational Oncology</i> , 2017, 19, 651-657.	1.2	75
39	Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 209-215.	1.5	135
40	Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 435-444.	5.2	172
41	Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevacizumab: A retrospective analysis. <i>Molecular and Clinical Oncology</i> , 2017, 6, 403-408.	0.4	8
42	European edition of the NCCN clinical practice guidelines: relevance of the translation and adaptation into Spanish. <i>Clinical and Translational Oncology</i> , 2017, 19, 288-290.	1.2	0
43	Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients. <i>Oncolmmunology</i> , 2017, 6, e1260214.	2.1	11
44	Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. <i>Supportive Care in Cancer</i> , 2017, 25, 3295-3304.	1.0	64
45	Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery. <i>Clinical Lung Cancer</i> , 2017, 18, 178-188.e4.	1.1	5
46	MicroRNA profiling associated with non-small cell lung cancer: next generation sequencing detection, experimental validation, and prognostic value. <i>Oncotarget</i> , 2017, 8, 56143-56157.	0.8	28
47	New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA. <i>Journal of Thoracic Disease</i> , 2017, 9, S1332-S1345.	0.6	13
48	The Quality Oncology Practice Initiative program: Experience in Spain.. <i>Journal of Clinical Oncology</i> , 2017, 35, 214-214.	0.8	1
49	Identification of quality care indicators in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 213-213.	0.8	0
50	Oncology beyond the hospital: 7 years taking care of cancer patients from the very beginning until the last consequences.. <i>Journal of Clinical Oncology</i> , 2017, 35, 75-75.	0.8	0
51	Study on compliance with breakthrough cancer pain guidelines by medical oncologists in Spain.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18260-e18260.	0.8	0
52	Serum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 12904-12916.	0.8	73
53	Circulating tumor cells versus circulating tumor DNA in lung cancer—“which one will win?”. <i>Translational Lung Cancer Research</i> , 2016, 5, 466-482.	1.3	72
54	Quality Indicators to Assure and Improve Cancer Care in Spain Using the Delphi Technique. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 553-558.	2.3	7

#	ARTICLE	IF	CITATIONS
55	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. <i>Annals of Oncology</i> , 2016, 27, 417-423.	0.6	122
56	High pKDR immunohistochemical expression is an unfavourable prognostic biomarker in patients with advanced colorectal cancer treated with chemotherapy plus bevacizumab. <i>Clinical and Translational Oncology</i> , 2016, 18, 405-412.	1.2	1
57	SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan. <i>Supportive Care in Cancer</i> , 2016, 24, 499-507.	1.0	11
58	Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers. <i>Oncotarget</i> , 2016, 7, 52849-52861.	0.8	33
59	Peritoneal Carcinomatosis and Multi-Organ Metastases are Prognostic Factors in Colorectal Cancer: A Retrospective Analysis. <i>Journal of Analytical Oncology</i> , 2016, 5, 5-13.	0.1	0
60	Differential expression of tumorspheres in CSC-markers and signaling pathways from non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23276-e23276.	0.8	0
61	EGFR mutant cfDNA and CTC detection as biomarkers in patients diagnosed with advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23039-e23039.	0.8	0
62	Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma. <i>Oral Diseases</i> , 2015, 21, 899-904.	1.5	27
63	Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage III Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1067-1075.	0.5	15
64	Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature. <i>BMC Urology</i> , 2015, 15, 15.	0.6	1
65	Isolation and characterization of lung cancer sphere-forming cells as platforms for the development of new therapeutic strategies.. <i>Journal of Clinical Oncology</i> , 2015, 33, e22190-e22190.	0.8	0
66	miRNA detection methods and clinical implications in lung cancer. <i>Future Oncology</i> , 2014, 10, 2279-2292.	1.1	29
67	MicroRNAs: Promising New Antiangiogenic Targets in Cancer. <i>BioMed Research International</i> , 2014, 2014, 1-14.	0.9	48
68	Interleukin-6 concentration changes in plasma and saliva in bisphosphonate-related osteonecrosis of the jaws. <i>Oral Diseases</i> , 2014, 20, 446-452.	1.5	15
69	Lungscape: Resected Non-Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1675-1684.	0.5	31
70	Variants in phospholipid metabolism and upstream regulators and non-small cell lung cancer susceptibility. <i>Clinical and Translational Oncology</i> , 2014, 16, 107-112.	1.2	4
71	Bladder cancer index: cross-cultural adaptation into Spanish and psychometric evaluation. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 20.	1.0	20
72	A Gene Signature Combining the Tissue Expression of Three Angiogenic Factors is a Prognostic Marker in Early-stage Non-small Cell Lung Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 612-620.	0.7	24

#	ARTICLE	IF	CITATIONS
73	Oxidative stress in bisphosphonate-related osteonecrosis of the jaws. <i>Journal of Oral Pathology and Medicine</i> , 2014, 43, 371-377.	1.4	34
74	Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies. <i>Annals of Oncology</i> , 2014, 25, 2147-2155.	0.6	27
75	Oncological translational research in the Spanish national health system: the INTRO study. <i>Clinical and Translational Oncology</i> , 2014, 16, 686-695.	1.2	0
76	Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists. <i>Clinical and Translational Oncology</i> , 2014, 16, 914-920.	1.2	6
77	Management of malignant insulinoma. <i>Clinical and Translational Oncology</i> , 2013, 15, 725-731.	1.2	28
78	SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013. <i>Clinical and Translational Oncology</i> , 2013, 15, 977-984.	1.2	18
79	Investigation of Complement Activation Product C4d as a Diagnostic and Prognostic Biomarker for Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1385-1393.	3.0	127
80	Customized chemotherapy in metastatic non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2013, 2, 180-8.	1.3	3
81	Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum. <i>Lung Cancer</i> , 2012, 76, 354-361.	0.9	29
82	Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 883-890.	1.1	22
83	Update on biomarkers for the detection of lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2012, 3, 21.	1.3	22
84	Pain in clinical oncology: Patient satisfaction with management of cancer pain. <i>European Journal of Pain</i> , 2012, 16, 381-389.	1.4	20
85	The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients. <i>Lung Cancer</i> , 2011, 72, 365-369.	0.9	43
86	Combined VEGF-A and VEGFR-2 concentrations in plasma: Diagnostic and prognostic implications in patients with advanced NSCLC. <i>Lung Cancer</i> , 2011, 74, 326-331.	0.9	48
87	Management of lung cancer-associated anaemia: the Spanish Lung Cancer Anaemia Survey (SLCAS). <i>Clinical and Translational Oncology</i> , 2011, 13, 328-334.	1.2	4
88	Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1260-1266.	0.5	46
89	The Role of Tumor-Infiltrating Immune Cells and Chronic Inflammation at the Tumor Site on Cancer Development, Progression, and Prognosis: Emphasis on Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 824-833.	0.5	276
90	The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. <i>British Journal of Cancer</i> , 2011, 104, 1168-1177.	2.9	244

#	ARTICLE	IF	CITATIONS
91	Chemotherapy-Induced Neutropenia Does Not Correlate With DNA Repair Gene Polymorphisms and Treatment Efficacy in Advanced Non-Small-Cell Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2011, 12, 224-230.	1.1	17
92	Analysis of the Prognostic Value of Soluble Epidermal Growth Factor Receptor Plasma Concentration in Advanced Non-Small-Cell Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2011, 12, 320-327.	1.1	15
93	Oncology outside hospital: a new experience for the benefit of longer survivors. <i>Clinical and Translational Oncology</i> , 2011, 13, 249-253.	1.2	4
94	The prognostic value of hTERT expression levels in advanced-stage colorectal cancer patients: a comparison between tissue and serum expression. <i>Clinical and Translational Oncology</i> , 2011, 13, 396-400.	1.2	10
95	Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04). <i>Clinical and Translational Oncology</i> , 2011, 13, 411-418.	1.2	0
96	Transdermal buprenorphine for the treatment of cancer pain: results from a multicenter, observational, post-marketing study in Spain (RELIEF study). <i>Pain Management</i> , 2011, 1, 513-522.	0.7	3
97	Circulating DNA is a Useful Prognostic Factor in Patients with Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 286-290.	0.5	75
98	The Role of Tumor Stroma in Cancer Progression and Prognosis: Emphasis on Carcinoma-Associated Fibroblasts and Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 209-217.	0.5	502
99	Professional survey on knowledge and clinical patterns of pain management in Spanish medical oncology. <i>Clinical and Translational Oncology</i> , 2010, 12, 819-824.	1.2	7
100	Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population. <i>BMC Cancer</i> , 2010, 10, 26.	1.1	24
101	Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3138-3145.	0.8	351
102	Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1683-1693.	0.9	10
103	Cisplatin plus vinorelbine as first-line treatment for advanced non-small-cell lung cancer: Is a hemogram on day 8 essential?. <i>Lung Cancer</i> , 2010, 68, 415-419.	0.9	8
104	Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients. <i>Lung Cancer</i> , 2010, 68, 491-497.	0.9	13
105	Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. <i>Journal of Translational Medicine</i> , 2010, 8, 135.	1.8	86
106	Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: A prognostic score from individual data of nine randomised trials. <i>European Journal of Cancer</i> , 2010, 46, 735-743.	1.3	71
107	Importance of Quality of Life in Patients with Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2009, 10, 83-90.	1.1	31
108	Professional burnout among Spanish medical oncologists. <i>Clinical and Translational Oncology</i> , 2009, 11, 86-90.	1.2	7

#	ARTICLE	IF	CITATIONS
109	Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients. <i>Clinical and Translational Oncology</i> , 2009, 11, 727-736.	1.2	3
110	Analysis of the elderly patient population in a tertiary-care university hospital. <i>European Journal of Cancer Care</i> , 2009, 18, 264-270.	0.7	2
111	Retrospective study of efficacy and toxicity on patients older than 70 years within a randomized clinical trial of two cisplatin-based combinations in patients with small-cell lung cancer. <i>Lung Cancer</i> , 2009, 63, 83-87.	0.9	13
112	Induction chemotherapy followed by concurrent chemoradiation for patients with non-operable stage III non-small-cell lung cancer. <i>Lung Cancer</i> , 2009, 63, 63-67.	0.9	11
113	Lung cancer and treatment in elderly patients: The Achilles Study. <i>Lung Cancer</i> , 2009, 66, 103-106.	0.9	18
114	Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer. <i>New England Journal of Medicine</i> , 2009, 361, 958-967.	13.9	2,213
115	Pharmacogenetics in lung cancer for the lay doctor. <i>Targeted Oncology</i> , 2008, 3, 161-171.	1.7	4
116	Can the Spanish care system assume the new costs of medications against cancer?. <i>Clinical and Translational Oncology</i> , 2008, 10, 96-101.	1.2	6
117	Study of the prevalence of tumour-related asthenia in Spanish cancer patients. <i>Clinical and Translational Oncology</i> , 2008, 10, 351-358.	1.2	2
118	Retrospective analysis of the prognostic role of p16 protein inactivation in plasma in patients with locally advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2008, 61, 104-108.	0.9	8
119	Efectos cutáneos adversos causados por erlotinib. <i>Actas Dermo-sifiligráficas</i> , 2008, 99, 54-60.	0.2	7
120	Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 2747-2754.	0.8	445
121	Use of free circulating DNA for diagnosis, prognosis and treatment of cancer. <i>Expert Opinion on Medical Diagnostics</i> , 2007, 1, 143-146.	1.6	0
122	Individual Patient Data Meta-Analysis of Docetaxel Administered Once Every 3 Weeks Compared With Once Every Week Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 1377-1382.	0.8	110
123	Gene Expression and Polymorphisms of DNA Repair Enzymes: Cancer Susceptibility and Response to Chemotherapy. <i>Clinical Lung Cancer</i> , 2007, 8, 369-375.	1.1	28
124	Oncologists'™ perceptions of cancer pain management in Spain: The real and the ideal. <i>European Journal of Pain</i> , 2007, 11, 352-359.	1.4	14
125	Venous thromboembolic disease in cancer. Optimisation of the use of antithrombotic agents. <i>Clinical and Translational Oncology</i> , 2007, 9, 161-171.	1.2	4
126	Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. <i>Lung Cancer</i> , 2006, 51, 143-158.	0.9	310

#	ARTICLE	IF	CITATIONS
127	Analysis of c-kit expression in small cell lung cancer: Prevalence and prognostic implications. Lung Cancer, 2006, 52, 343-347.	0.9	29
128	Dr. Neri et al.: Prognostic role of K-ras mutations in non-small cell lung cancer: Still an issue for open debate. Lung Cancer, 2006, 53, 397-398.	0.9	3
129	Anorexiaâ€“Cachexia syndrome in cancer: implications of the ubiquitinâ€“proteasome pathway. Supportive Care in Cancer, 2006, 14, 1173-1183.	1.0	28
130	Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Annals of Oncology, 2006, 17, 467-472.	0.6	117
131	Pharmacogenomics and gemcitabine. Annals of Oncology, 2006, 17, v13-v16.	0.6	25
132	Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Annals of Oncology, 2006, 17, 668-675.	0.6	159
133	Quantification in the serum of the catalytic fraction of reverse telomerase: a useful prognostic factor in advanced non-small cell lung cancer. Anticancer Research, 2006, 26, 4905-9.	0.5	12
134	Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Annals of Oncology, 2005, 16, 1081-1086.	0.6	217
135	Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer. Annals of Oncology, 2005, 16, 597-601.	0.6	23
136	14-3-3 β Methylation in Pretreatment Serum Circulating DNA of Cisplatin-Plus-Gemcitabine-Treated Advanced Nonâ€“Small-Cell Lung Cancer Patients Predicts Survival: The Spanish Lung Cancer Group. Journal of Clinical Oncology, 2005, 23, 9105-9112.	0.8	114
137	Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up?. Lung Cancer, 2005, 49, 1-12.	0.9	133
138	Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?. Lung Cancer, 2005, 50, 339-346.	0.9	47
139	Weekly paclitaxel as second/third-line treatment in advanced non-small cell lung cancer patients: efficacy and tolerability. Anticancer Research, 2005, 25, 4611-4.	0.5	6
140	Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients. Clinical Cancer Research, 2004, 10, 1318-1325.	3.2	345
141	Epirubicinâ€“cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. Annals of Oncology, 2004, 15, 79-87.	0.6	69
142	The role of the clinical research coordinator â€“ data manager â€“ in oncology clinical trials. BMC Medical Research Methodology, 2004, 4, 6.	1.4	54
143	Effect of the Methylene tetrahydrofolate Reductase C677T Polymorphism on Patients with Cisplatin/Gemcitabineâ€“Treated Stage IV Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2004, 5, 360-365.	1.1	21
144	Single nucleotide polymorphisms and outcome in docetaxelâ€“cisplatin-treated advanced non-small-cell lung cancer. Annals of Oncology, 2004, 15, 1194-1203.	0.6	270

#	ARTICLE	IF	CITATIONS
145	Prospective Randomized Phase III Trial of Etoposide/Cisplatin Versus High-Dose Epirubicin/Cisplatin in Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2004, 6, 175-183.	1.1	31
146	Assessment of Nucleotide Excision Repair XPD Polymorphisms in the Peripheral Blood of Gemcitabine/Cisplatin-Treated Advanced Non-Small-Cell Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2003, 4, 237-241.	1.1	48
147	Targeted therapy in combination with gemcitabine in non-small cell lung cancer. <i>Seminars in Oncology</i> , 2003, 30, 19-25.	0.8	34
148	Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2003, 42, 345-354.	0.9	47
149	Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21). <i>Journal of Clinical Oncology</i> , 2003, 21, 833-842.	0.6	145
150	Cisplatin Plus Gemcitabine Versus a Cisplatin-Based Triplet Versus Nonplatinum Sequential Doublets in Advanced Non-Small-Cell Lung Cancer: A Spanish Lung Cancer Group Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 3207-3213.	0.8	177
151	Influence of genetic markers on survival in non-small cell lung cancer. <i>Drugs of Today</i> , 2003, 39, 775.	2.4	33
152	Raltitrexed in the treatment of elderly patients with advanced colorectal cancer. <i>European Journal of Cancer</i> , 2002, 38, 1204-1211.	1.3	28
153	Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy. <i>Cancer</i> , 2002, 95, 2408-2413.	2.0	11
154	Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2002, 8, 2286-91.	3.2	532
155	Phase II Trial of Paclitaxel Plus Gemcitabine in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 1071-1077.	0.8	45
156	Preoperative High-Dose Cisplatin Versus Moderate-Dose Cisplatin Combined with Ifosfamide and Mitomycin in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Results of a Randomized Multicenter Trial. <i>Clinical Lung Cancer</i> , 2000, 1, 287-293.	1.1	12
157	Corrigendum to "Second line treatment with gemcitabine and vinorelbine in non-small-cell lung cancer (NSCLC) cisplatin failures: a pilot study". <i>Lung Cancer</i> , 2000, 29, 227.	0.9	0
158	Second-line treatment with gemcitabine and vinorelbine in non-small-cell lung cancer (NSCLC) cisplatin failures: a pilot study. <i>Lung Cancer</i> , 2000, 27, 47-53.	0.9	29
159	Cisplatin and vinorelbine combination chemotherapy in inoperable non small cell lung cancer (NSCLC): a multicenter phase II trial. <i>Lung Cancer</i> , 2000, 2, 84-90.		1
160	Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. <i>Lung Cancer</i> , 1999, 26, 7-14.	0.9	367
161	Modified weekly regimen with vinorelbine as a single agent in unresectable non-small cell lung cancer. <i>Lung Cancer</i> , 1997, 17, 261-269.	0.9	16
162	Mutated K-ras gene analysis in a randomized trial of preoperative chemotherapy plus surgery versus surgery in Stage IIIA non-small cell lung cancer. <i>Lung Cancer</i> , 1995, 12, S59-S70.	0.9	24

#	ARTICLE	IF	CITATIONS
163	A Randomized Trial Comparing Preoperative Chemotherapy Plus Surgery with Surgery Alone in Patients with Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 1994, 330, 153-158.	13.9	1,204
164	Epirubicin plus a calmodulin inhibitor (trifluoperazine) activity in advanced pancreatic adenocarcinoma. <i>European Journal of Cancer</i> , 1994, 30, 1043.	1.3	4
165	Re: "Treatment of Advanced Colorectal Cancer with Recombinant Interferon Alpha and Fluorouracil: Activity in Liver Metastasis" <i>Cancer Investigation</i> , 1994, 12, 101-102.	0.6	0
166	5-Fluorouracil, folinic acid, epidoxorubicin and cisplatin (FLEP) combination chemotherapy in advanced measurable gastric cancer. A phase II trial of the Spanish Cooperative Group for Gastrointestinal Tumor Therapy. <i>Annals of Oncology</i> , 1993, 4, 753-757.	0.6	15
167	Treatment of Advanced Colorectal Cancer with Recombinant Interferon Alpha and Fluorouracil: Activity in Liver Metastasis. <i>Cancer Investigation</i> , 1992, 10, 259-264.	0.6	17
168	Cytophagic histiocytic panniculitis. <i>Journal of the American Academy of Dermatology</i> , 1989, 20, 875-878.	0.6	22
169	Epidermoid carcinoma of the colon. <i>Diseases of the Colon and Rectum</i> , 1986, 29, 665-667.	0.7	8